TCGA-2F-A9KR-01A-11R-A38B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 104.5663601
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.220
- KRAS_SIGNALING_DN+0.180
- NOTCH_SIGNALING+0.150
- OXIDATIVE_PHOSPHORYLATION+0.100
- P53_PATHWAY+0.060
- PEROXISOME+0.060
- PI3K_AKT_MTOR_SIGNALING+0.050
- HYPOXIA-0.010
- TGF_BETA_SIGNALING-0.010
- WNT_BETA_CATENIN_SIGNALING-0.040
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- ALLOGRAFT_REJECTION-0.430
- IL2_STAT5_SIGNALING-0.430
- INFLAMMATORY_RESPONSE-0.430
- COAGULATION-0.350
- COMPLEMENT-0.350
- KRAS_SIGNALING_UP-0.350
- INTERFERON_GAMMA_RESPONSE-0.320
- MYC_TARGETS_V2-0.310
- ANGIOGENESIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.852 |
| 2 | MBCProject_0004_T1_RNA | — | C | 0.832 |
| 3 | SRR650165 | — | — | 0.826 |
| 4 | TCGA-S3-AA11-01A-31R-A41B-07 | — | B | 0.825 |
| 5 | TCGA-DK-A1AG-01A-11R-A13Y-07 | — | — | 0.822 |
| 6 | SRR1069188 | GTEX | — | 0.816 |
| 7 | TCGA-CF-A27C-01A-11R-A16R-07 | — | — | 0.813 |
| 8 | MDT-AP-0402 | Med | Medulloblastoma | 0.809 |
| 9 | DRR168599 | — | — | 0.806 |
| 10 | SRR1362060 | GTEX | — | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |